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Abstract
Coincident with the expanding population of aged people, the incidence of Alzheimer disease (AD) is rapidly increasing in
most advanced countries. At present, no effective prophylactics are available. Among several pathological mechanisms
proposed for AD, the ‘‘amyloid hypothesis’’ has been most widely accepted, in which accumulation or deposition of Ab is
considered to be the initial event. Thus, prevention of Ab production would be an ideal strategy for the treatment or
prevention of AD. Ab is produced via the proteolytic cleavage of its precursor protein, APP (amyloid precursor protein), by
two different enzymes, b and c-secretases. Indeed, inhibitors against either or both enzymes have been developed and
tested for clinical efficacy. Based on the ‘‘amyloid hypothesis’’, we developed a luciferase-based screening method to
monitor c-secretase activity, screened more than 1,600 plant extracts, most of which have long been used in Chinese
medicine, and observed that Hop extracts significantly inhibit Ab production in cultured cells. A major component of the
inhibitory activity was purified, and its chemical identity was determined by NMR to be Garcinielliptone HC. In vivo, oral
administration of Hop extracts to AD model mice decreased Ab depositions in the cerebral cortex of the parietal lobe,
hippocampus, and artery walls (amyloid angiopathy) in the brains. In a Morris water maze test, AD model mice that had
daily consumed Hop extracts in their drinking water showed significant mitigation of memory impairment at ages of 9 and
12 months. Moreover, in the open field test oral administration of Hop extracts also prevented an emotional disturbance
that appeared in the AD mice at 18 months. Despite lifelong consumption of Hop extracts, no deleterious side effects were
observed at any age. These results support the ‘‘amyloid hypothesis’’, and indicate that Hop extract is a promising candidate
for an effective prophylactic for AD.
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Introduction
Alzheimer Disease (AD) is the most frequently observed
neurodegenerative disorder, in Japan and other advanced
countries [1,2,3]. Several inhibitors for cholinesterase, e.g.
donepezil (Aricept), are available for mitigating clinical pheno-
types, but are not able to inhibit the progression of neuronal cell
death; thus, the long-term prognosis has not appreciably changed
[4,5]. In the brains of AD patients, two major pathologies have
been observed, namely Ab depositions and neurofibrillary tangles
[1]. Ab is a small peptide, 40 or 42 amino acids in length, which is
derived from APP (amyloid precursor protein) [6] through
cleavage by b- and c-secretases [7,8]. Neurofibrillary tangles are
composed of hyper-phosphorylated tau proteins [9].
Several pathological mechanisms have been proposed for AD.
Among them, and most widely accepted, is the ‘‘amyloid
hypothesis’’, which posits that accumulation/deposition of Ab is
the initial event, which in turn induces neurofibrillary tangles,
leading to neuronal dysfunction and neuronal cell death [10,11].
The ‘‘amyloid hypothesis’’ has been supported by several clinical
observations [12]. First, the APP gene itself, which is located on
human chromosome 21, is responsible for one of the familial forms
of AD with dominant inheritance [13,14,15]. Two other loci for
familial forms of AD with dominant inheritance, on chromosome
14 and 1, have been shown to encode two related proteins,
presenilin 1 and 2, respectively, and both are now known to be
components of c-secretase [16,17]. All identified APP and
presenilin mutants from AD patients produce more Ab42 or
aggregation-prone mutated Ab than normal APP and presenilins,
respectively [18,19]. Furthermore, a recent cohort study in Iceland
identified AD resistant pedigrees. These people possess a novel
amino acid substitution (A673T) in APP, near the b-secretase
cleavage site, resulting in decreased Ab production [20].
Based on the ‘‘amyloid hypothesis’’, several strategies to
decrease Ab production/accumulation have been tried, but any
clinically successful therapeutic method or drug has not been
reported. Even in the brains of healthy individuals, Ab deposition
starts in the forties [21]. It may take 20 years or more to complete
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the deposition, then another 20 years or more to manifest MCI
(mild cognitive impairment), with a wide range of variability [22].
In AD patients, these processes tend to proceed rapidly, eventually
leading to ‘‘dementia’’ as early as the fifties [23]. Thus,
prophylactic drugs for reducing Ab production, if available, would
be best taken as early as the forties, and should be continued for
the next several decades. Thus, for such prophylactic drugs, safety
and lack of side effects is a critical requirement. From this
perspective, we assumed that plant extracts used in Chinese
medicine would be good candidates, because they have been taken
by humans for more than a thousand years and are basically safe
for humans when administered in moderate doses. In this study,
we found that Hop flower extracts partially inhibit Ab production,
and that continuous oral administration of Hop flower extracts
ameliorates not only Ab deposition but also memory and
emotional impairments of AD model mice, with no obvious side
effects.
Materials and Methods
Cell culture and transfection
HEK293A cells were grown at 37uC in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum.
Plasmid transfection was carried out using Lipofectamine plus
(Invitrogen), according to the manufacturer’s protocol. Cells in a
24-well dish were co-transfected with 200 ng each, of the plasmids
pCMX-FLAG-bCTF (wild-type, V717F (Indiana mutation) [14],
or V717I (London mutation) [15])-Gal4VP16, pCMX-b-galacto-
sidase, and pTK-(GalRE)x4-Luc [24]. For evaluating Notch-
cleaving activities, we transfected 200 ng pCMX-caNotch1-
Gal4VP16, in which a constitutive active Notch1 fragment [25]
was fused with Gal4VP16 at the C-terminus. All luciferase values,
except for those from Notch1 cleavage, were obtained from the
transfection of pCMX-FLAG-bCTF(V717F)-Gal4VP16. For west-
ern blotting, HEK293A cells were transfected with 300 ng of
pCMX-FLAG-bCTF(V717F)-Gal4VP16 and 300 ng of pCMX-
GFP. Twenty-four hours after transfection, DAPT, Hop extracts,
or the purified compound was added, and then incubated an
additional 24 hours. 10 mg of cell lysates were analyzed by western
blot. Anti-FLAG, anti-GAL4, anti-GFP, and anti-actin were
purchased from Sigma-Aldrich (MO, USA), Abcam (MA, USA),
Nacalai Tesque (Kyoto, Japan), and Millipore (MA, USA),
respectively.
Ethanol extracts of plants
Ethanol extracts of plants used in Chinese medicine were
purchased from an import company.
Luciferase and b-galactosidase assays
Twenty-four hours after transfection, different amounts of test
compounds in vehicle (DMSO or methanol) or vehicle alone were
added to the culture medium, and then incubated for an
additional 24 hours. Then, cells were harvested, whole cell
extracts were prepared, and luciferase and b-galactosidase assays
were carried out, as described previously [26]. The obtained raw
luciferase activities were normalized by the b-galactosidase
activities to compensate for different transfection efficiencies.
ELISA
To quantify the amounts of Ab40 and Ab42, harvested culture
media and whole cell extracts were prepared from the transfected
HEK293A cells. The culture media was assayed using a human b
amyloid (1–40) or (1–42) ELISA kit (WAKO), and the values
obtained were normalized by the b-galactosidase activities of the
corresponding cell extracts.
Bligh-Dyer method
The Bligh-Dyer method was performed, as described previously
[27,28]. Briefly, 100 mg Hop extract was mixed with 3.8 ml of
chloroform: methanol: water (1 ml: 2 ml: 0.8 ml). To the resulting
mixture, 1 ml of chloroform was added and mixed, and then 1 ml
of water was added and mixed. The mixture was centrifuged at
1,500 rpm for 10 min. The upper layer (water-soluble fraction:
Fraction 1) and the lower layer (lipid-soluble fraction: Fraction 2)
were separately collected. Both fractions were dried and weighed.
The yields were 23 mg and 76 mg in Fraction 1 and Fraction 2,
respectively.
Solid-phase extraction
The dried lipid-soluble fraction (Fraction 2) from the Bligh-Dyer
method was dissolved in hexane: chloroform (50:50), and was
applied to a Sep-Pak Vac 35 cc (10 g) silica cartridge (Waters).
Separation procedures are described in Figure legends.
HPLC purification
HPLC was performed using an Alliance 2690 HPLC system
(Waters) with columns of COSMOSIL 5CN-MS (106250 mm)
(Nacalai Tesque), COSMOSIL 5C18-AR-II (106250 mm) (Na-
calai Tesque), Symmetry Shield C18 (4.66250 mm) (Waters), and
COSMOSIL p-NAP (4.66250 mm) (Nacalai Tesque). Separation
procedures for each column are described in the respective
Figure legends.
LC/MS analyses
The purified compound was analyzed by LC/MS using a 2795
separation module/Thermo Finnigan, LCQ Deca XP plus
(Waters) [29,30].
NMR analysis
NMR analysis was performed using a JNM-LA 500 (JEOL).
The values obtained were the following: 1H NMR (500 MHz,
CDCl3) d 4.81–4.76 (m, 3H), 3.64 (m, 1H), 2.93 (dd, J = 14.4,
10.9 Hz, 1H), 2.82 (dd, J = 14.4, 8.0 Hz, 1H), 2.70-2.59 (m, 4H),
1.57 (s, 6H), 1.52 (s, 6H), 1.30 (s, 3H), 1.24 (s, 3H), 1.23 (d,
J = 6.3 Hz, 3H), 1.21 (d, J = 6.9 Hz, 3H); 13C NMR (125 MHz,
CDCl3) d 204.8, 202.3, 199.3, 158.1, 135.2, 135.0, 118.1, 117.7,
108.9, 102.3, 92.5, 72.0, 61.8, 39.2, 37.4, 34.9, 26.5, 25.8, 25.7,
25.1, 24.3, 20.1, 18.8, 17.9, 17.7. The calculated value of HRMS
(FAB) C25H37O5 [(M+H)+] was 417.2641, and the observed value
was 417.2632.
Transgenic mice
The AD mice were established following a standard procedure
using the C57BL/6 strain [29,31]. The mice expressed a FLAG-
tagged C-terminal portion of human APP (bCTF) with the
Indiana mutation (V717F) in neuronal cells, driven by a neuron-
specific enolase (NSE) promoter. The homozygous transgenic mice
(V717F mice) were maintained and used for experiments. We also
created another AD model mouse by co-injecting two NSE
promoter-driven transgenes, one for FLAG-bCTF(V717F) and the
other for HA-tagged full-length mutant presenilin 1 (P267S) [32].
The heterozygous transgenic mice (V717F/P267S mice) were used
for experiments, as noted in the Results and figure legends. These
mice are available via CARD (Center for Animal Resources and
Development) in Kumamoto University on request. All animal
studies were approved by the Review Board of Kyoto University.
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Real-time RT-PCR
Total mouse brain RNA was purified from 9-month old mice
(n = 3 for each genotype), using TRIsure (BIOLINE), following the
manufacturer’s protocol. 300 ng of the purified RNA was used for
cDNA synthesis with random primers and M-MLV reverse
transcriptase (Promega). Real-time quantitative PCR was per-
formed on a LightCycler System (Roche Diagnostics) using DNA






Morris water maze behavioral analysis
Morris water maze behavioral analysis was performed as
described previously [33]. An escape platform (666 cm) was
submerged 0.5 cm under the surface of the 21–22uC water in a
circular tank (0.7 m in diameter and 0.2 m high). A DCR-TRV20
(SONY) camera was placed above the tank, and recorded the
movements of the mice. The first 2 days of testing consisted of
non-spatial training and acclimating the mice to the water and the
platform. The next 5 days consisted of memory training with 4
trials each day, with the platform placed in the same quadrant.
The latencies were determined by measuring the time to reach the
platform. Twenty-four hours after the final trial, the platform was
removed and the mice were given probe trials to test their memory
of the hidden platform. The lengths of time that mice stayed in
each quadrant were calculated over the 5-minute duration of the
test. The open field test was performed as described previously
[34]. Briefly, each mouse was placed in the center of a circular box
(75 cm in diameter) and was allowed to freely explore for 5 min,
under a standard fluorescent light. Three zones were set in the box
(zone 3, center of the circle, with a 15 cm diameter; zone 1, the
outer-most annulus, with a width of 15 cm; zone 2, the annulus
between zone 1 and zone 3, with a width of 15 cm). A DCR-
TRV20 (SONY) camera was placed above the field, and recorded
the movements of the mice. During the test, the time spent in
zones 2 and 3 was calculated using SMART software (version 2.0,
Panlab).
Y-maze test
The maze was made of black painted wood; each arm was
40 cm in length, 12 cm in height, 5 cm in width at the bottom.
The arms were oriented at 120u with respect to each other. A
mouse was placed at the center of the apparatus and allowed to
move freely through the maze during an 8-min session. The
alternation behavior (%) was calculated as the ratio of actual
alternations to possible alternations, as described [35,36].
Histochemical analyses
Mouse brains were fixed with 4% paraformaldehyde overnight
and then embedded in paraffin, and sagittal sections were
prepared with a thickness of 3 mm. The sections were treated
with a monoclonal anti-Ab antibody (1–16) diluted 1:200, (6E10,
Covance) [37]. Immune signals were detected with a Vectostain
elite ABC standard kit (Vector laboratories), following the
manufacturer’s protocol. The stereomorphological analyses were
performed on 5 randomly selected regions (40,000 mm2 for each)
of the each section of the parietal lobe from the mouse brain (n = 3
for each genotypes) by BZ-9000 Generation II microscopy
(KEYENCE) with its analysis application programs [38]. FSB
staining was performed following the manufacturer’s protocol
[39]. Briefly, the sagittal sections of brains were deparaffinized and
immersed in 0.01% FSB in 50% ethanol for 30 min. Then, the
sections were differentiated in saturated Li2CO3 and rinsed in
50% ethanol. The fluorescence images were obtained with
AxioVision (Zeiss).
Statistical analysis
The statistical significance was analyzed using repeated
measures two-way ANOVA followed by a Holm-Sidak test or
Tukey’s post-hoc, or Student’s t test.
Results
Screening of plant extracts that inhibit Ab production
We previously developed an assay in which proteolytic activities
directed at membrane proteins can be converted to a transcrip-
tional activity readout [24]. We constructed a similar system to
monitor the cleavage of APP by c-secretase (Fig. 1A). In this
system, Gal4VP16, a chimeric transcription factor, was fused to
the FLAG-tagged C-terminal end of the b-C-terminal fragment of
APP (bCTF), and the resulting FLAG-bCTF-Gal4VP16 fusion
protein was expressed in HEK293A cells, together with a
luciferase reporter plasmid, which contains 4 copies of GalRE
[24], a Gal4-responsive element in the promoter region. We also
co-transfected a plasmid expressing b-galactosidase for the
normalization of transfection efficiencies. Twenty-four hours after
the transfection, measurable levels of both luciferase and b-
galactosidase were observed. In the presence of DAPT, a
commercially available c-secretase inhibitor, luciferase but not b-
galactosidase activity was decreased, indicating that this system
can monitor the inhibition of c-secretase (Fig. 1B). By ELISA, we
confirmed the decrease of Ab production in the presence of DAPT
(Fig. 1C).
Using this luciferase assay system, we screened ethanol-extracts
of more than 1,600 plants, most of which are currently used in
Chinese medicine, and found that among them Hop flower
extracts had the most potent inhibitory activity toward the
luciferase reporter. Hop flower extracts showed similar inhibitory
activities toward the cleavage of substrates with Indiana (V717F)
or London (V717I) mutations (Fig. 1B, D), but less efficient
inhibition of Notch1 cleavage (Fig. 1D). The inhibitory activity
was dose-dependent (Fig. 1B, C, D). We observed very little
inhibitory activity in water-extracts of Hop flowers. These results
indicated that the responsible molecule(s) is lipid-soluble. Using
ELISA, we confirmed that ethanol-extracts of Hop decreased
production of both Ab40 and Ab42 (Fig. 1C). These results
indicated that ethanol-extracts of Hop flowers (referred to as ‘‘Hop
extracts’’ hereafter) contain molecule(s) that inhibit c-secretase.
Isolation and identification of a major c-secretase-
inhibitory component from Hop extracts
In order to isolate major components of Hop extracts that
inhibit c-secretase, we first performed a Bligh-Dyer separation
protocol (Fig. S1). As expected, the inhibitory activities were
detected in the lipid-soluble fraction (Fraction 2) (Fig. S2). Next,
we separated Fraction 2 by solid-phase extraction with a Sep-Pak
Vac Silica cartridge: firstly eluted by with 100% chloroform
(Fraction 2-1), followed by 100% methanol (Fraction 2-2). We
found that the inhibitory activities were eluted in Fraction 2-2, but
not Fraction 2-1 (Fig. 2A). We then applied Fraction 2-2 to
normal-phase HPLC analysis with a 5CN-MS column, and
observed that the inhibitory activities were eluted in Fractions 4-7
(Fig. S3). We next applied Fractions 4–7 to reverse-phase HPLC
analysis with a COSMOSIL 5C18-AR-II column, and observed
Anti-AD Effects of Hop Flower Extracts
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Figure 1. Hop extracts inhibit Ab production. (A) Schematic drawing of the luciferase-based c-secretase assay. The b-C-terminal fragment of
APP (bCTF) was expressed in HEK293A cells as a fusion protein with Gal4VP16, a chimeric transcriptional factor, together with a luciferase-expressing
reporter plasmid containing the thymidine kinase (TK) promoter with 4 copies of a Gal4-responsive element (GalRE) [24]. As an internal control of
transfection, a b-galactosidase-expressing plasmid was also co-transfected. When bCTF-Gal4VP16 was cleaved by c-secretase, the APP intracellular
domain (AICD)-Gal4VP16 fusion was released and translocated into the nucleus, where it activated transcription of the luciferase reporter gene.
Luciferase and b-galactosidase activities in whole cell extracts were measured. (B) Quantification of relative luciferase activities. Twenty-four hours
after transfection with the plasmids for bCTF(V717F)-Gal4VP16 and b-galactosidase, HEK293A cells were treated with or without different amounts of
Anti-AD Effects of Hop Flower Extracts
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that the inhibitory activities were eluted in Fractions 9–12
(Fig. 2B). We then applied Fractions 9–12 to additional reverse
phase HPLC analysis with a Symmetry Shield C18 column, and
found that the inhibitory activities were eluted in Fractions 15–16
(Fig. 2C).
Lastly, we applied Fractions 15–16 to a COSMOSIL p-NAP
reverse-phase HPLC column, and observed a single peak that
eluted in Fraction 15 (Fig. 3A). We confirmed that the purified
compound indeed retained the ability to inhibit Ab production, as
evidenced by the luciferase assay (Fig. 3B). The estimated IC50
values of the purified compound and DAPT were 5.4 mg/mL and
29 nM, respectively, the latter of which was comparable to the
known IC50 value of DAPT (20 nM) [40]. It is notable, however,
that the specific activity relative to the initial Hop extracts did not
appreciably increase over the course of the purification (see
discussion). By western blot, we examined the cleavage products in
lysates from HEK293A cells transfected with the FLAG-
bCTF(V717F)-Gal4VP16 construct. As reported previously
[41,42], it was very difficult to detect AICD. However, DAPT
increased the amounts of aCTF due to the decrease of c-cleavage.
Very similar to DAPT, both Hop extracts and the purified
compound increased the amounts of aCTF (Fig. 3C). These
results further support the idea that Hop extracts and the purified
compound suppress c-secretase activity.
We also measured the optical absorbance profile of the purified
compound (Fig. 3D). Two absorbance peaks at 247 and 332 nm
were assigned to a, b- and a, b, c, d-unsaturated carbonyl bonds,
respectively (Fig. 3E). We then determined its molecular mass by
LS/MS to be 416 g/mole (Fig. 3E). Repeated purifications
yielded a total of approximately 2 mg of the purified compound.
We then analyzed its chemical structure by NMR and found that
its NMR values perfectly fit with those of a previously reported
compound, Garcinielliptone HC [43], and its chemical formula
was determined to be C25H36O5 (Fig. 3E).
Amelioration of AD phenotypes in AD model mice by
continuous oral administration of Hop extracts
We next examined the in vivo effects of Hop extracts on AD
model mice, in which the FLAG-tagged b-C-terminal fragment of
APP (bCTF) with Indiana mutation (V717F) was expressed under
the control of the NSE (neuron-specific enolase) promoter. These
transgenic mice were mated to obtain homozygous mice, and then
the homozygous mice were bred to achieve sufficient numbers
(referred to as V717F mice hereafter). For the experiments, V717F
mice were separated into two groups. In one group, mice were
allowed to drink water freely. In the other group, mice were
allowed to freely drink Hop extract-containing water (2 g extract
per liter of water) after weaning. In both groups and age-matched
wild-type mice, total amounts of water consumption did not differ,
approximately 4,6 ml/day/mouse (Fig. 4A). Body weights also
did not differ between all 3 groups throughout the examination
periods, up to 18 months of age (Fig. 4B). In both groups of
V717F mice, expression of the transgene mRNAs in the brain
were not statistically different (Fig. 4C), indicating that the Hop
extract did not affect the NSE promoter activity or stability of the
transgene mRNA.
At 2 months of age, both groups of V717F mice did not display
any impairment of spatial memory in the Morris water maze test,
as compared with age-matched wild-type mice (Fig. 4D). At 9
months of age, water-drinking V717F mice showed significant
impairment in spatial memory in the Morris water maze test.
These mice needed more time to reach the hidden platform, as
compared with the age-matched wild-type mice. In contrast, Hop
extract-drinking V717F mice were able to reach the hidden
platform significantly faster than the water-drinking V717F mice.
The ability of the Hop extract-drinking V717F mice to reach the
platform appeared equal to or even slightly better than the age-
matched wild-type mice (Fig. 4D). By 12 months, Hop extract-
drinking V717F mice were still able to reach the hidden platform
significantly faster than the water-drinking V717F mice, but
apparently slower than the age-matched wild-type mice (Fig. 4D).
In the follow-up probe test, water-drinking V717F mice spent a
similar time around the area where the hidden platform had been
placed, as compared to the time spent in the other area. However,
the age-matched wild-type mice or Hop extract-drinking V717F
mice spent significantly more time around the area where the
hidden platform had been placed than in the other area, at ages of
9 as well as 12 months (Fig. 4E).
We noted that no significant difference in basal activities were
observed in the 3 groups of mice, up to ages of 18 months (Fig. 4F,
left panel), and thus the observed differences in time to reach the
hidden platform were not due to differences in physical activities.
At ages of 15 and 18 months, however, a significant difference in
time to reach the hidden platform was no longer observed between
water-drinking V717F mice and Hop extract-drinking V717F
mice (data not shown). These results indicate that Hop extracts
have the ability to delay the V717F phenotypes but not to
completely prevent their manifestation. In the open field test, by
which not only basal activities but also emotional states were able
to be examined, all 3 groups of mice behaved indistinguishably at
ages of 6, 12, and 15 months (Fig. 4F, right panel). At ages of 18
months, only water-drinking V717F mice displayed significantly
longer times away from the walls, indicating that the water-
drinking V717F mice were impaired in feeling anxiety, a type of
emotional disturbance, and that Hop extracts might prevent
emotional disturbances in AD as well.
We also created another transgenic AD model mouse, in which
the FLAG-bCTF(V717F) and full-length mutant presenilin 1
(P267S) were co-expressed under the control of the NSE
promoter. These transgenic mice were maintained as heterozygous
mice (referred as to V717F/P267S mice hereafter), and were
subjected to memory tests. Up to 7 months of age, V717F/P267S
mice did not display any impairment of spatial memory in the
Morris water maze test, as compared with age-matched wild-type
DAPT, a commercially available c-secretase inhibitor in DMSO (D), or HOP flower extracts (HFE) in methanol (M). Twenty-four hours after the
treatments, whole cell extracts were prepared and the luciferase and b-galactosidase activities were measured. Mean values of relative luciferase
activities, after normalization with b-galactosidase activities, are shown, with values for DMSO alone (D) set at 1.0. Error bars indicate standard
deviations. *p,0.05, **p,0.01 by Student’s t test. (C) Quantification of relative Ab40 and Ab42 amounts by ELISA. The amounts of Ab40 and Ab42
released into the culture medium in B were measured by ELISA. Mean values of relative ELISA values, after normalization with b-galactosidase
activities, are shown, with values for DMSO alone (D) set at 1.0. Error bars indicate standard deviations. *p,0.05, **p,0.01, ***p,0.005 by Student’s t
test. (D) Quantification of relative luciferase activities. Twenty-four hours after transfection with plasmids expressing b-galactosidase and bCTF(V717I)-
Gal4VP16 (left panel) or caNotch1-Gal4VP16 (right panel), HEK293A cells were treated with or without different amounts of DAPT in DMSO (D) or HOP
flower extracts (HFE) in methanol (M). Twenty-four hours after the treatments, whole cell extracts were prepared and the luciferase and b-
galactosidase activities were measured. Mean values of relative luciferase activities, after normalization with b-galactosidase activities, are shown,
with values for DMSO alone (D) set at 1.0. Error bars indicate standard deviations. *p,0.05, **p,0.01 by Student’s t test.
doi:10.1371/journal.pone.0087185.g001
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mice (Fig. S4). At 9 months of age, however, water-drinking
V717F/P267S mice showed significant impairment in spatial
memory in the Morris water maze test, similar to the impairment
observed in water-drinking V717F mice. These V717F/P267S
mice needed more time to reach the hidden platform, as compared
with the age-matched wild-type mice. In contrast, Hop extract-
drinking V717F/P267S mice were able to reach the hidden
platform significantly faster than the water-drinking V717F/
P267S mice. The ability of the Hop extract-drinking V717F/
P267S mice to reach the platform was comparable to the age-
matched wild-type mice (Fig. 4G).
In the probe test, water-drinking V717F/P267S mice spent a
similar time around the area where the hidden platform had been
placed, as compared to the time spent in the other area. However,
the age-matched wild-type mice or Hop extract-drinking V717F/
P267S mice spent significantly more time around the area where
the hidden platform had been placed than in the other area
(Fig. 4H). Consistently, water-drinking V717F/P267S mice
showed significantly reduced proficiency of special memory in a
Y-maze test, as compared to the age-matched wild-type mice or
Hop extract-drinking V717F/P267S mice (Fig. 4I).
Finally, we examined whether Hop extracts were indeed able to
reduce Ab depositions in the brain of our V717F model mice. We
sacrificed 16-month old mice and examined their brains by
immunohisotchemical analyses. On first inspection, we had the
impression that the brains of water-drinking V717F mice were
smaller than those of the others, but the differences were not
significant. In the cerebral cortex of the frontal lobe (areas
Figure 2. Purification of a major component in Hop extract that inhibits Ab production. (A) Results of the luciferase assay after solid phase
extraction. 330 mg of the lipid-soluble fraction (Fraction 2) from the Bligh-Dyer method was applied to a Sep-Pak Vac Silica Cartridge, and was eluted
with 100% chloroform (fraction 2-1), followed by 100% methanol (fraction 2-2). Each fraction was dried and dissolved in methanol (M), then assayed
for inhibition of Ab production using the luciferase assay, as described in Fig. 1B. Mean values of relative luciferase activities, after normalization with
b-galactosidase activities, are shown, with values for DMSO alone (D) set at 1.0. Bars denote standard deviations. *p,0.05, **p,0.01 by Student’s t
test. (B) A representative chromatogram from the first reverse-phase HPLC is shown (upper panel). 180 mg of Fractions 4–7 from the normal-phase
HPLC (Fig. S1 and S3) were applied to a COSMOSIL 5C18-AR-II column, and were eluted with a linear gradient of acetonitrile, starting from 80% to
100% for 20 min, followed by continuous flow with 100% acetonitrile. Effluent fractions were collected every minute. The results of the luciferase
assay for each fraction are shown (lower panel). Fractions 9–12 were pooled and used for further purification. (C) A representative chromatogram
from the second reverse-phase HPLC is shown (upper panel). 26 mg of pooled fractions 9–12 in (B) was applied to a symmetry shield C18 column,
and was eluted following the same procedures as in (B). Effluent fractions were collected at 1-minute intervals. The results of the luciferase assay for
each fraction are shown (lower panel). Fractions 15–16 were pooled and used for further purification.
doi:10.1371/journal.pone.0087185.g002
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indicated by black boxes in Fig. 5A), we could not observe any
clear difference of Ab deposition among water-drinking V717F
mice, Hop extract-drinking V717F mice, and age-matched wild-
type mice. In the cerebral cortex of the parietal lobe (areas
indicated by red boxes in Fig. 5A), very large amounts of Ab
deposition were observed in water-drinking V717F mice. Howev-
er, the Ab deposition was greatly reduced in age-matched Hop
extract-drinking V717F mice. Slight Ab deposition was observed
in the cerebral cortex of the parietal lobe in the age-matched wild-
type mice (Fig. 5B and C). Similar results were observed by FSB
staining (Fig. 5C and Fig. S5). Furthermore, in the hippocampus
(areas indicated by blue boxes in Fig. 5A), Ab deposition was
much reduced in Hop extract-drinking V717F mice compared
with water-drinking V717F mice. It is notable that in water-
drinking V717F mice, Ab deposition was clearly observed around
certain artery walls, albeit infrequently, which is termed ‘‘amyloid
angiopathy’’ [44], but such ‘‘amyloid angiopathy’’ was barely
observed in age-matched Hop extract-drinking V717F mice or
Figure 3. Characterizations of the purified compound. (A) A representative chromatogram from the third reverse-phase HPLC is shown (upper
panel). 7.3 mg of pooled fractions 15–16 in Fig. 2C were applied to a COSMOSIL p-NAP column, and were eluted by continuous flow with 65%
acetonitrile. The compound was eluted at 15 min as a single peak. (B) Comparison of DAPT and the purified compound by the luciferase assay. The
estimated IC50 value of the purified compound was 5.4 mg/mL. (C) Comparison of DAPT, Hop extracts (HFE), and the purified compound (Fraction 15)
by western blot analysis of the cleavage products of exogenously expressed FLAG-bCTF(V717F)-Gal4VP16 in HEK293A lysates. Positions of FLAG-
bCTF(V717F)-Gal4VP16 (non-cleaved) and aCTF-Gal4VP16 (aCTF-GV) are shown. GFP served as an internal control of the transfection, and actin served
as a loading control. (D) Optical absorbance profile of the purified compound. (E) LC/MS profile of the purified compound. The molecular mass of the
purified compound was determined as 416 g/mol; obtained value of M+H was 417.2632. The molecular architecture of the purified compound,
determined by NMR, is also shown. Note that the chemical formula of the compound was C25H36O5.
doi:10.1371/journal.pone.0087185.g003
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wild-type mice (Fig. 5D). In Hop extract-drinking V717F and
wild-type mice, we did not observe any obvious skin problems, e.g.
acne inversa [45,46], skin cancers [47,48], etc. up to ages of 18
months (see Discussion).
Discussion
The ‘‘amyloid hypothesis’’ predicts that reduction of Ab
production or accumulation would be an effective strategy for
the treatment or prevention of AD. Accordingly, one approach has
focused on the development of inhibitors of c-secretase, whose
activity is crucial to overall Ab production as well as the Ab40/
Ab42 ratio. Indeed, Semagacestat, an investigational compound,
was developed and was tested in clinical trials on AD patients, but
the trials did not show any significant slowing of AD phenotypes,
or even worsened the symptoms in a phase III clinical study [48].
In addition, an increased risk of skin cancers has been reported
[48], which might be due to inhibition of Notch signaling
pathways by the c-secretase inhibitor [47].
Recently, it has been proposed that enhanced activation of c-
secretase may promote the degradation of Ab and thus lead to
reduced Ab accumulation [49]. An alternative approach was to
neutralize Ab by Ab immunization or with Ab-specific antibodies.
Such biological drugs, e.g. Bapineuzumab, were developed, and
their efficacies were tested in large clinical trials, but no benefit was
observed [50,51]. In addition, during anti-Ab immunotherapies,
several patients incurred intracranial hemorrhaging or meningo-
encephalitis as a complication, which prompted the discontinua-
tion of the clinical trials [52]. The hemorrhaging was assumed to
be caused by the Ab antibody reacting with amyloid angiopathy.
The failures of these trials for AD treatment notwithstanding, a
recent cohort study in Iceland brought new strong evidence
supporting the idea that reducing Ab indeed reduces AD risk. The
study identified an AD-resistant mutation (A673T) in APP near
the b cleavage site [20]. In cell culture experiments, the mutated
APP produced approximately half the amount of Ab than non-
mutated APP. Thus, individuals possessing one allele of the
mutated APP gene should have a 25% reduction of Ab production
[20]. Given that such individuals showed very low risk of AD, mild
inhibition of Ab production might be optimal for avoiding AD. As
shown in this study, Hop-extracts contain mild activities that
partially inhibit Ab production in cultured cells, and indeed they
proved to be markedly effective in preventing not only learning
and memory impairment but also Ab depositions in AD model
mice. These results support the ‘‘amyloid hypothesis’’ and are
consistent with the idea that mild inhibition of Ab production is a
plausible strategy to reduce AD risk [53]. Moreover, we did not
observe any skin problems throughout the administration of Hop
extracts up to 18 months, indicating that mild inhibition of c-
secretase is not deleterious.
In humans, it is generally believed that memory disturbance in
AD patients occurs long after the completion of Ab deposition. By
contrast, in our V717F mice, neurological phenotypes apparently
precede the completion of Ab deposition. In 16-month old V717F
mice, administration of Hop extracts was still visibly apparent as
reduced Ab deposition, but at that age, the Hop extract-drinking
mice had already lost memory ability to levels similar to those of
water-drinking V717F mice. These apparent differences notwith-
standing, our results demonstrating that Hop extracts have the
ability to reduce Ab deposition as well as to forestall memory
impairment in the AD model mice consistently support the
importance of Ab production for the onset of AD.
In this study, we also succeeded in purifying a major active
component in Hop extracts that inhibits c-secretase. As often
observed in the purification procedures of plant extracts, specific
activities were not substantially increased during the purification.
This result raises the possibility that the inhibitory activity of the
purified compound might be enhanced synergistically with other
components in the hop extracts. As is often observed in Chinese
medicine, the single usage of the purified compound by itself might
not be effective for AD. By mass analysis, its molecular weight was
determined to be 416, and its chemical structure was solved by
NMR analysis and was found to be Garcinielliptone HC [43].
This compound was originally isolated from Garcinia, suggesting
that Garcinia extracts might also have the potential to reduce Ab
production or accumulation. This possibility remains to be tested.
Future studies are necessary to reveal the mechanism of inhibition.
In addition to the observed Ab-reducing activity, Hop-extracts
have been reported to contain other interesting properties,
including anti-inflammatory activities [54], estrogen-like activities
Figure 4. Mitigation of memory impairment in AD model mice by oral administration of Hop extracts. (A) Average daily water
consumption per mouse, per experimental group. Decrease of water volume in each water bottle was measured every 7 days. No significant
difference was observed in the amount of water consumed, comparing the three groups. (B) Body weights of wild-type mice, water-drinking V717F
mice, and Hop extract-drinking V717F mice, from age 3 months to 18 months. Bars represent standard deviations. No significant difference was
observed among the groups of mice. (C) Quantitative RT-PCR analysis of transgene mRNA in the brains of water-drinking V717F mice and Hop
extract-drinking V717F mice. Brain mRNAs from 9-month old water-drinking V717F mice and Hop extract-drinking V717F mice were analyzed by
quantitative RT-PCR to determine the expression levels of the transgene mRNA. No significant difference was observed among the groups. (D) Morris
water maze test with V717F mice. The test measured the time required for mice to locate a hidden platform. At ages of 2 months, no significant
difference was observed among the groups of mice. At ages of 9 and 12 months, Hop extract-drinking V717F mice (n = 7), required significantly
shorter times to reach the hidden platform, compared with water-drinking V717F mice (n = 7). F = 11.4, p,0.001 in 9-month-old mice, F = 20.94, p,
0.01 in 12-month-old mice, by two-way repeated measures ANOVA followed by a Holm-Sidak test. Bars indicate standard deviation. (E) Probe test in
the Morris water maze test. At ages of 2 months, all 3 groups of mice spent significantly more time in the quadrant where the hidden platform had
been placed. At ages of 9 and 12 months, water-drinking wild-type mice (n = 7) and Hop extract-drinking V717F mice (n = 7) showed a significantly
prolonged stay in the quadrant where the hidden platform had been placed, but this ability was lost in water-drinking AD mice (n = 7). Bars indicate
standard deviation. *p,0.05, **p,0.01 by Student’s t test. (F) Open field test for basal activity and anxiety. At ages of 6, 12, 15, and 18 months, no
significant differences in basal activity were observed among the three groups. However, at 18 months, water-drinking AD mice (n = 7) stayed a
significantly longer period in zone 2 or zone 3, as compared with age-matched wild-type (n = 8) or Hop extract-drinking AD mice (n = 7). F = 6.58,
**p,0.01 by repeated measures two-way ANOVA, Tukey’s post-hoc. (G) Morris water maze test with V717F/P267S mice. At ages of 9 months, Hop
extract-drinking V717F/P267S mice (n = 7), required significantly shorter times to reach the hidden platform, compared with water-drinking V717F/
P267S mice (n = 5). F = 8.51, p,0.05 by two-way repeated-measures ANOVA followed by Holm-Sidak test. Bars indicate standard deviation. (H) Probe
test in the Morris water maze test. At ages of 9 months, water-drinking wild-type mice (n = 8) and Hop extract-drinking V717F/P267S mice (n = 7)
showed a significantly prolonged stay in the quadrant where the hidden platform had been placed, but such prolonged stay was lost in water-
drinking V717F/P267S mice (n = 7). Bars indicate standard deviation. *p,0.05, **p,0.01 by Student’s t test. (I) Y-maze test with V717F/P267S mice. At
ages of 9 months, water-drinking V717F/P267S mice showed significantly higher percent alternation, compared with water-drinking wild-type or Hop
extract-drinking V717F/P267S mice. Bars indicate standard deviation. **p,0.01 by Student’s t test.
doi:10.1371/journal.pone.0087185.g004
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[55,56], anti-atherosclerotic activities [57], etc. It has long been
argued that chronic inflammation may be a mechanism under-
lying AD [58,59], and recent clinical studies indicate that estrogen
therapy reduced the risk of AD, especially for young postmeno-
pausal women [60,61]. These additional Hop activities might also
add some benefits to the prevention or retardation of AD
progression. Hop extracts have long been used in Chinese
medicine for sedation, calming gastric and intestinal disorders,
diuretics, etc. In Europe, Hop flower has been used as an herb for
the treatment of insomnia, neuralgia, and menopausal disorders
[62,63]. Furthermore, from their estrogen-like activities, Hop
extracts have been tested in several clinical trials for reducing post-
menopausal complications, at a maximal dose of 300 mg/day, and
no obvious side effects were reported [64].
Recently, c-secretase mutations have been reported to cause
acne inversa [45,46]. In our mouse experiments, more than one
Figure 5. Mitigation of Ab depositions in V717F mice by oral administration of Hop extracts. (A) Histochemical analyses of mouse brains
stained by an anti-Ab antibody. Sagittal sections of brains of 16-month old mice (n = 3 in each) were stained with an anti-Ab antibody. Ab depositions
were visualized (brown color) by the ABC method. Scale bars, 200 mm. (B) Quantification of Ab depositions in sections of parietal lobes (areas
indicated by red boxes in A) with a BZ-9000 Generation II microscope (KEYENCE) and image analysis application programs. Bars indicate standard
deviation. **p,0.01 by Student’s t test. (n = 15 for each, see details inMaterials and methods). (C) Histochemical analysis of sections in the cerebral
cortex of the parietal lobe of mouse brains stained by FSB, an amyloid sensitive fluorescent dye. Scale bars, 200 mm. (D) A representative photo of
amyloid angiopathy. At 16 months, the Ab deposition in the artery wall was specifically observed in the brains of water-drinking AD mice, but not in
those of age-matched wild-type and Hop extract-drinking AD mice. Scale bars, 50 mm.
doi:10.1371/journal.pone.0087185.g005
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and a half years of daily administration of Hop extracts did not
manifest acne inversa nor elicit any overt deleterious effects. These
lines of evidence encourage us to further investigate Hop extracts
as safe and promising anti-AD substances. Finally, it should be
mentioned that Hop sub-species contain different levels of c-
secretase inhibitory activities, and some have no measurable
activity at all. Growing locales and conditions might also affect the
activities. Thus, quality control of the extracts will be critical for
maximizing the prophylactic effects on AD.
Supporting Information
Figure S1 A schematic flow diagram of the purification
procedures.
(TIFF)
Figure S2 Quantification of inhibition of Ab production
by fractions from the Bligh-Dyer method. Mean values of
relative luciferase activities from cells treated with DAPT and
Fractions 1 and 2 of Bligh-Dyer method, after normalization with
b-galactosidase activities, are shown. Values in the absence of test
compounds (0) are set at 1.0. Error bars indicate standard
deviations. *p,0.05, **p,0.01
(TIFF)
Figure S3 Quantification of inhibition of Ab production
by fractions from the first normal-phase HPLC. A
representative chromatogram of the normal-phase HPLC is
shown (upper panel). 250 mg of Fraction 2-2 from the solid phase
extraction (Fig. 2A) were applied to a COSMOSIL 5CN-MS
column, and were eluted by a linear gradient of methanol, from
0% to 15% over 15 min, in hexane: chloroform (1:1), followed by
continuous flow of 15% methanol in Hexane: chloroform (1:1).
Effluent fractions were collected every minute. The results of the
luciferase assay on each fraction are shown (lower panel).
(TIFF)
Figure S4 Morris water maze test with V717F/P267S
mice. The test measured the time required for mice to locate a
hidden platform. At ages of 5 and 7 months, no significant
difference was observed among the groups of mice.
(TIFF)
Figure S5 Enlarged images of FSB staining. Sections of
the cerebral cortex of the parietal lobe (CTX) and the
hippocampus (HC), from 16-month old mice, were stained by
FSB. Scale bars, 20 mm. Stronger FSB signals were observed in the
sections from water-drinking V717F mice (V717F) than those from
age-matched wild-type mice (WT).
(TIFF)
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